FEIBA prophylaxis for patients with haemophilia and inhibitors

Haemophilia

Volumn 12, Issue SUPPL. 5, 2006, Pages 26-31

  Valentino, Leonard A ^a  

^a Rush Children's Hospital and Rush University Medical Center   (United States)

Author keywords

Arthropathy; FEIBA; Hemarthrosis; Inhibitors; Prophylaxis

Indexed keywords

ACTIVATED PROTHROMBIN COMPLEX; ALLOANTIBODY; AUTOANTIBODY; BLOOD CLOTTING FACTOR 8 CONCENTRATE; FEIBA VH; RECOMBINANT BLOOD CLOTTING FACTOR 7A;

ANTIBODY TITER; ARTICLE; BLEEDING; BREAKTHROUGH BLEEDING; CATHETER INFECTION; CENTRAL VENOUS CATHETERIZATION; CLINICAL TRIAL; COST BENEFIT ANALYSIS; COST CONTROL; DISEASE SEVERITY; DRUG COST; DRUG DOSE REGIMEN; DRUG TREATMENT FAILURE; EVIDENCE BASED MEDICINE; HEMARTHROSIS; HEMOPHILIA; HEMOPHILIA A; HEMOPHILIA B; HEMOSTASIS; HIGH RISK PATIENT; HUMAN; IMMUNOLOGICAL TOLERANCE; JOINT FUNCTION; JOINT INJURY; LONG TERM CARE; PRIORITY JOURNAL; QUALITY OF LIFE; SYNOVITIS; THROMBOSIS;

EID: 33750293981     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2006.01382.x     Document Type: Article

References (41)

1. Manco-Johnson M. Hemophilia management: Optimizing treatment based on patient needs. Curr Opin Pediatr 2005; 17: 3-6.
2. Berntorp E. Prophylactic therapy for haemophilia: Early experience. Haemophilia 2003; 9: 5-9; discussion, 9.
3. Aledort LM, Haschmeyer RH, Pettersson H. A longitudinal study of orthopaedic outcomes for severe factor-VIII-deficient haemophiliacs. The Orthopaedic Outcome Study Group. J Intern Med 1994; 236: 391-9.
4. Nilsson IM, Berntorp E, Lofqvist T, Pettersson H. Twenty-five years'experience of prophylactic treatment in severe haemophilia A and B. J Intern Med 1992; 232: 25-32.
5. Panicker J, Warrier I, Thomas R, Lusher JM. The overall effectiveness of prophylaxis in severe haemophilia. Haemophilia 2003; 9: 272-8.
6. van den Berg HM, Fischer K, van der Bom JG, Roosendaal G, Mauser-Bunschoten EP. Effects of prophylactic treatment regimens in children with severe haemophilia: A comparison of different strategies. Haemophilia 2002; 8: 43-6.
7. van den Berg HM, Fischer K. Prophylaxis for severe hemophilia: experience from Europe and the United States. Semin Thromb Hemost 2003; 29: 49-54.
8. Van den Berg HM, Dunn A, Fischer K, Blanchette VS. Prevention and treatment of musculoskeletal disease in the haemophilia population: Role of prophylaxis and synovectomy. Haemophilia 2006; 12: 159-68.
9. Manco-Johnson MJ. Update on treatment regimens: Prophylaxis versus on-demand therapy. Semin Hematol 2003; 40: 3-9.
10. Shapiro AD, Donfield SM, Lynn HS et al. Defining the impact of hemophilia: The Academic Achievement in Children with Hemophilia Study. Pediatrics 2001; 108: E105.
11. Berntorp E, Boulyjenkov V, Brettler D et al. Modern treatment of haemophilia. Bull World Health Organ 1995; 73: 691-701.
12. Medical and Scientific Advisory Council. MASAC Recommendation Concerning Prophylaxis (Regular Administration of Clotting Factor Concentrate to Prevent Bleeding). MASAC Recommendation 170. National Hemophilia Foundation, 2006. Available at http://www.hemophilia.org/NHFWeb/MainPgs/ MainNHF.aspx?menuid=57&contentid=582. Accessed May 19, 2006.
13. Srivastava A, Giangrande P, Poon MC, Chua M, McCraw A, Wiedel J. Guidelines for the management of hemophilia. Available at: http://www.wfh.org/2/docs/Publications/Diagnosis_and_Treatment/ Gudelines_Mng_Hemophilia.pdf. Accessed May 19, 2006.
14. Valentino LA. Secondary prophylaxis therapy: What are the benefits, limitations and unknowns? Haemophilia 2004; 10: 147-57.
15. Valentino L. FEIBA prophylaxis in hemophilia A patients with inhibitors results in 95%; reduction in bleeding episodes. Poster presented at: XXVI International Congress of the World Federation of Hemophilia; October 17-21, 2004; Bangkok, Thailand.
16. Leissinger CA. Use of prothrombin complex concentrates and activated prothrombin complex concentrates as prophylactic therapy in haemophilia patients with inhibitors. Haemophilia 1999; 5: 25-32.
17. Rodriguez-Merchan EC. Surgery in haemophilic patients with inhibitors. Haemophilia 2004; 10: 1-2.
18. Fischer K, van der Bom JG, Mauser-Bunschoten EP et al. The effects of postponing prophylactic treatment on long-term outcome in patients with severe hemophilia. Blood 2002; 99: 2337-41.
19. Rodriguez-Merchan EC. Pathogenesis, early diagnosis, and prophylaxis for chronic hemophilic synovitis. Clin Orthop Relat Res 1997; 343: 6-11.
20. Silva M, Luck JV Jr, Llinás A. Chronic hemophilic synovitis: The role of radiosynovectomy. Treatment of Hemophilia Monograph Series [No. 33]. Available at: http://www.wfh.org/2/docs/Publications/ Musculoskeletal_Physiotherapy/TOH-33_English_Synovectomy.pdf. Accessed May 19, 2006.
21. Greene WB, McMillan CW. Nonsurgical management of hemophilic arthropathy. Instr Course Lect 1989; 38: 367-81.
22. Aledort L. Inhibitors in hemophilia patients: Current status and management. Am J Hematol 1994; 47: 208-17.
23. Ho AY, Height SE, Smith MP. Immune tolerance therapy for haemophilia. Drugs 2000; 60: 547-54.
24. Kreuz W, Escuriola-Ettinghausen C, Mentzer D et al. Factor VIII inhibitor bypass activity (FEIBA) for prophylaxis during immune tolerance induction (ITI) in patients with high-responding inhibitors [abstract]. Blood 2000; 96: 266a. Abstract 1141.
25. DiMichele DM, Kroner BL. The North American Immune Tolerance Registry: practices, outcomes, outcome predictors. Thromb Haemost 2002; 87: 52-7.
26. Mariani G, Siragusa S, Kroner BL. Immune tolerance induction in hemophilia A: A review. Semin Thromb Hemost 2003; 29: 69-76.
27. FEIBA VH [package insert]. Westlake Village, CA: Baxter Healthcare Corporation, 2000.
28. Turecek PL, Varadi K, Gritsch H et al. Factor Xa and prothrombin: mechanism of action of FEIBA. Vox Sang 1999; 77: 72-9.
29. Turecek PL, Varadi K, Gritsch H, Schwarz HP. FEIBA: Mode of action. Haemophilia 2004; 10: 3-9.
30. Negrier C, Goudemand J, Sultan Y, Bertrand M, Rothschild C, Lauroua P, the French FEIBA Study Group. Multicenter retrospective study on the utilization of FEIBA in France in patients with factor VIII and factor IX inhibitors. Thromb Haemost 1997; 77: 1113-9.
31. Tjonnfjord GE. Activated prothrombin complex concentrate (FEIBA) treatment during surgery in patients with inhibitors to FVIII/IX: The updated Norwegian experience. Haemophilia 2004; 10: 41-5.
32. Kreuz W, Escuriola-Ettinghausen C, Martinez I, Mentzer D, Figura S, Klarmann D. Efficacy and safety of factor VIII inhibitor bypass activity (FEIBA) for long-term prophylaxis in patients with high-responding inhibitors [abstract]. Blood 2000; 96: 265a. Abstract 1140.
33. Hilgartner MW, Makipernaa A, DiMichele DM. Long-term FEIBA prophylaxis does not prevent progression of existing joint disease. Haemophilia 2003; 9: 261-8.
34. Siegmund B, Richter H, Pollmann H. Prophylactic treatment with FEIBA of a haemophilia A patient with inhibitor: What are the costs, what are the benefits? Haemophilia 2005; 11: 638-41.
35. DiMichele D, Negrier C. A retrospective postlicensure survey of FEIBA efficacy and safety. Haemophilia 2006; 12: 352-62.
36. Ewenstein BM, Valentino LA, Journeycake JM et al. Consensus recommendations for use of central venous access devices in haemophilia. Haemophilia 2004; 10: 629-48.
37. Valentino LA, Kapoor M. Central venous access devices in patients with hemophilia. Expert Rev Med Devices 2005; 2: 699-711.
38. Carcao MD, Connolly BL, Chait P et al. Central venous catheter-related thrombosis presenting as superior vena cava syndrome in a haemophilic patient with inhibitors. Haemophilia 2003; 9: 578-83.
39. Collins PW, Khair KS, Liesner R, Hann IM. Complications experienced with central venous catheters in children with congenital bleeding disorders. Br J Haematol 1997; 99: 206-8.
40. A prospective, randomized, cross-over study of an activated prothrombin complex concentrate for secondary prophylaxis in patients with hemophilia A and inhibitors. Available at: http://www.clinicaltrial.gov/ ct/show/NCT00221195?order=6. Accessed August 2, 2006.
41. Leissinger CA. Prevention of bleeds in hemophilia patients with inhibitors: Emerging data and clinical direction. Am J Hematol 2004; 77: 187-93.